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  As the scientific community scrambles to define the ancestry 
and lineages of the eight segments of new pandemic H1N1 
strain, we looked for unique genetic events in this virus’s 
genome  to  explain  the  newly  found  enhanced  virulence 
and transmissibility among humans. Genome annotations 
of this virus identified a stop mutation replacing serine at 
codon 12 (S12Stop) of the PB1-F2 protein, a virulence factor 
in influenza A viruses. Here, we discuss the significance of 
this finding and how it may contribute to host specialization, 
explaining  the  virtual  absence  of  the  H1N1  influenza  A 
virus strain in pig populations. This finding is expected to 
lead  to  a  better  understanding  of  the  transmission  and 
pathogenesis of the 2009 pandemic strain.
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The success of influenza viruses lies in their ability to 
infect and replicate in a host by constantly changing the 
immunogenic pocket on the surface-exposed hemagglutinin 
molecule. Another hallmark of this successful pathogen is 
its ability to establish itself in an intracellular niche, outrace 
the host innate immune responses, and exit the host using 
one of the several cell egress pathways before a sustained 
adaptive immune response is generated. 
One cell exit pathway used by viruses is to induce cell 
death by manipulating host apoptotic pathways [2]. One of 
the three proteins encoded by internal start sites of the 
segment 2 (PB1) of the RNA polymerase, PB1-F2, has 
been shown to localize in the inner mitochondrial 
membrane and orchestrate programmed cell death or 
apoptosis [12,13]. Furthermore, it has been demonstrated 
that the amino acid (aa) at position 66 of PB1-F2 affects the 
pathogenicity of an H5N1 virus in mice. The N66S 
mutation contributed to the high pathogenicity of the 1918 
pandemic A/Brevig Mission/18 virus, and its replacement 
(S66N) attenuated this virus in mice [2]. Therefore, 
PB1-F2 has been identified as a key virulence factor 
among influenza A viruses.
Extensive amino acid sequence analysis of the 2009 
(H1N1) influenza A pandemic viruses by our group (n = 
397) and others [4,9,10] revealed a major change in 
PB1-F2 in these strains. A point mutation in nucleotide 129 
(C→A change) led to the formation of a STOP codon in 
place of serine [11], truncating PB1-F2 to an 11 amino acid 
(aa) peptide instead of the typical, full-length 90 aa protein 
generally seen in swine viruses (Fig. 1). This change 
appears to be the one unique genetic event that separates 
the 2009 pandemic strain from its recent ancestors. 
Therefore, we seek an explanation of how this change may 
be involved in the newly found enhanced transmissibility, 
virulence, and pathogenicity of this pandemic strain of 
influenza A virus among humans. 
Recent studies on PB1-F2 polymorphisms in influenza 
virus strains associated with major outbreaks in swine 
since the 1950s have identified three possible truncation 
mutations after codons 11, 25, and 34, all of which were 
conserved across other lineages of influenza A viruses 
suggesting a functional consequence to these mutations 
[14]. Truncated proteins have been shown to have a more 
cytoplasmic distribution in the cell in contrast to the 
mitochondrial inner membrane distribution of full-length 
proteins, a possible reason for sustained viral replication in 
cells and increased proinflammatory responses [14]. Our 
analysis of 12 virus isolates from clinical swine influenza 
episodes in the US showed that 11 carry a full length 
PB1-F2 (87-90 aa) and one had a truncated (57 aa) protein, 
suggesting that minor truncations have not played a role in 
severe disease seen in pigs in the recent past. On the other 
hand, if major truncations in PB1-F2 previously ameliorated 
disease in pigs, they have not been found in this study. 
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Fig. 1. The amino acid sequence alignment of the PB1-F2 segment of representative avian, human, and swine influenza isolates. 
Alignments were generated using Clustal W. All 2009 pandemic strains of influenza A carry the S12Stop mutation (yellow) while 11
recent swine isolates (green) have full length or near full length PB1-F2 segment. One pig isolate had a 57 aa PB1-F2 (purple). Stop 
codon is shown as an asterisk (*). 
(H1N1) influenza virus revealed that it replicates efficiently 
and causes more severe pathological lesions in mice, ferrets, 
and non-human primates than a currently circulating seasonal 
human H1N1 virus [6]. Similar findings on pathogenicity 
and transmissibility of the 2009 pandemic H1N1 viruses 
have been described in the ferret model [8]. In contrast, 
relatively mild clinical signs/disease have been described 
in pigs inoculated with the 2009 pandemic H1N1 strain [7]. 
These findings support the hypothesis that the truncated 
PB1-F2 carried by the current 2009 pandemic H1N1 may 
be associated with relatively milder infections in pigs in 
contrast to those identified in experimental animals and 
humans. 
Studies of the 1918 pandemic strain of influenza suggested 
that a variant of PB1-F2 that carries eight amino acid 
changes throughout its full-length protein relative to more 
recent strains suggests that this protein is probably involved 
in virulence and pathogenicity [2,3]. In another study, one 
mutation shared by the 1918 strain of flu and Hk/97 was 
shown to be sufficient for pathogenicity [3]. It is also 
suggested that strains carrying the truncated PB1-F2 may 
not be efficient in inducing apoptosis and may produce less 
inflammation [5]. To date, all of the 2009 pandemic (H1N1) 
isolates have a PB1-F2 truncation. Therefore, we hypothesize 
that this truncated PB1-F2 may play an important role in 
the pathogenicity and tranmissibility of 2009 pandemic 
H1N1. 
Other questions related to the biology of these viruses 
also arise - Does this S12Atop polymorphism in PB1-F2 
lead to a variation in host specificity or host adaptation 
resulting in less severe disease in swine host versus a 
sustained infection in humans? Does the localization of 
PB1-F2 in the cytoplasm versus mitochondria lead to 
greater efficiency in viral replication? A synthetic peptide 
of PB1-F2 has been shown to be a potent pro-apoptotic 
factor, and a C-terminal peptide has been shown to be 
proinflammatory [1]. 
Next, does a truncation mutation that rescues only 11 amino S12STOP mutation in PB1-F2 of pandemic influenza A    351
acids of the N-terminal part of 2009 H1N1 strain explain, 
in part, the enhanced virulence or replication efficiency of 
this virus in human hosts? Or does this peptide even get 
stably translated in the cells? Experimental studies with 
pigs have shown low pathogenicity that may be related to 
the truncation of PB1-F2. We, therefore, propose that a better 
understanding of the pathogenesis will come from studies 
on PB1-F2 peptide, and whole virus (with the truncated 
PB1-F2 or complemented full-length PB1-F2) inoculation 
studies in animal models. Such studies should also address 
the replication and transmission efficiencies in and among 
a variety of hosts. Retrospective analyses of influenza A 
viruses isolated from clinically and pathologically well- 
characterized swine populations would be necessary to 
understand the natural history and emergence of this new 
pandemic strain.
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